Literature DB >> 12435766

Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

Abdel Babiker, Janet Darbyshire, Patrizio Pezzotti, Kholoud Porter, Giovanni Rezza, Sarah A Walker, Valerie Beral, Roel Coutinho, Julia Del Amo, Noël Gill, Christine Lee, Laurence Meyer, Freya Tyrer, Francois Dabis, Rodolphe Thiebaut, Sylvie Lawson-Aye, Faroudy Boufassa, Osamah Hamouda, Klaus Fischer, Patrizio Pezzotti, Giovanni Rezza, Giota Touloumi, Angelos Hatzakis, Anastasia Karafoulidou, Olga Katsarou, Ray Brettle, Jorge del Romero, Maria Prins, Birgit van Benthem, Ole Kirk, Court Pederson, Idelfonso Hernández Aguado, Santiago Pérez-Hoyos, Anne Eskild, Johan N Bruun, Mette Sannes, Caroline Sabin, Christine Lee, Anne M Johnson, Andrew N Phillips, Patrick Francioli, Philippe Vanhems, Mathias Egger, Martin Rickenbach, David Cooper, John Kaldor, Lesley Ashton, Jeanette Vizzard, Roberto Muga, Nicholas E Day, Daniela De Angelis.   

Abstract

BACKGROUND: Although studies have reported large reductions in the risks of AIDS and death since the introduction of potent anti-retroviral therapies, few have evaluated whether this has been similar for all AIDS-defining diseases. We wished to evaluate changes over time in the risk of specific AIDS-defining diseases, as first events, using data from individuals with known dates of HIV seroconversion.
METHODS: Using a competing risks proportional hazards model on pooled data from 20 cohorts (CASCADE), we evaluated time from HIV seroconversion to each first AIDS-defining disease (16 groups) and to death without AIDS for four calendar periods, adjusting for exposure category, age, sex, acute infection, and stratifying by cohort. We compared results to those obtained from a cause-specific hazards model.
RESULTS: Of 6,941, 2,021 (29%) developed AIDS and 437 (6%) died without AIDS. The risk of AIDS or death remained constant to 1996 then reduced; relative hazard = 0.89 (95% CI: 0.77-1.03); 0.90 (95% CI: 0.81-1.01); and 0.32 (95% CI: 0.28-0.37) for 1979-1990, 1991-1993, and 1997-2001, respectively, compared to 1994-1996. Significant risk reductions in 1997-2001 were observed in all but two AIDS-defining groups and death without AIDS in a competing risks model (with similar results from a cause-specific model). There was significant heterogeneity in the risk reduction across events; from 96% for cryptosporidiosis, to 17% for death without AIDS (P < 0.0001).
CONCLUSION: These findings suggest that studies reporting a stable trend for particular AIDS diseases over the period 1979-2001 may not have accounted for the competing risks among other events or lack the power to detect smaller trends.

Entities:  

Mesh:

Year:  2002        PMID: 12435766      PMCID: PMC4710780          DOI: 10.1093/ije/31.5.951

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  20 in total

1.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

2.  Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS).

Authors:  M Dorrucci; M Balducci; P Pezzotti; A Sinicco; F Alberici; G Rezza
Journal:  J Acquir Immune Defic Syndr       Date:  1999-09-01       Impact factor: 3.731

3.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

Authors:  D M Forrest; E Seminari; R S Hogg; B Yip; J Raboud; L Lawson; P Phillips; M T Schechter; M V O'Shaughnessy; J S Montaner
Journal:  Clin Infect Dis       Date:  1998-12       Impact factor: 9.079

4.  Models for the incubation of AIDS and variations according to age and period.

Authors:  A Muñoz; J Xu
Journal:  Stat Med       Date:  1996 Nov 15-30       Impact factor: 2.373

5.  Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  O Kirk; C Pedersen; A Cozzi-Lepri; F Antunes; V Miller; J M Gatell; C Katlama; A Lazzarin; P Skinhøj; S E Barton
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

6.  Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

Authors: 
Journal:  HIV Med       Date:  2000-10       Impact factor: 3.180

7.  Survival after introduction of HAART in people with known duration of HIV-1 infection. The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.

Authors: 
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

8.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

9.  AIDS across Europe, 1994-98: the EuroSIDA study.

Authors:  A Mocroft; C Katlama; A M Johnson; C Pradier; F Antunes; F Mulcahy; A Chiesi; A N Phillips; O Kirk; J D Lundgren
Journal:  Lancet       Date:  2000-07-22       Impact factor: 79.321

10.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

View more
  17 in total

1.  AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment.

Authors:  Kathleen Falster; Jun Yong Choi; Basil Donovan; Chris Duncombe; Brian Mulhall; David Sowden; Jialun Zhou; Matthew G Law
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

2.  Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries.

Authors: 
Journal:  AIDS       Date:  2014-10-23       Impact factor: 4.177

3.  Nonparametric Assessment of Differences Between Competing Risk Hazard Ratios: Application to Racial Differences in Pediatric Chronic Kidney Disease Progression.

Authors:  Derek K Ng; Daniel A Antiporta; Matthew B Matheson; Alvaro Muñoz
Journal:  Clin Epidemiol       Date:  2020-01-20       Impact factor: 4.790

4.  HIV aspartyl protease inhibitors as promising compounds against Candida albicans André Luis Souza dos Santos.

Authors:  André Luis Souza Dos Santos
Journal:  World J Biol Chem       Date:  2010-02-26

5.  Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Authors:  Sara Lodi; Marguerite Guiguet; Dominique Costagliola; Martin Fisher; Andrea de Luca; Kholoud Porter
Journal:  J Natl Cancer Inst       Date:  2010-05-04       Impact factor: 13.506

6.  A comparison of ad hoc methods to account for non-cancer AIDS and deaths as competing risks when estimating the effect of HAART on incident cancer AIDS among HIV-infected men.

Authors:  Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson
Journal:  J Clin Epidemiol       Date:  2009-10-31       Impact factor: 6.437

7.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

8.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

9.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

10.  Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.

Authors:  Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone
Journal:  J Acquir Immune Defic Syndr       Date:  2008-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.